Cantargia Overview

  • Founded
  • 2010
  • Status
  • Public
  • Employees
  • 19
  • Stock Symbol
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $2.69
  • (As of Friday Closing)

Cantargia General Information


Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • Scheelevägen 27
  • 223 63 Lund
  • Sweden
+46 046-275 00 00

Cantargia Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cantargia Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.69 $2.68 $2.53 - $8.34 $269M 100M 941K -$0.24

Cantargia Financials Summary

In Thousands,
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 307,391 735,214 137,036 83,120
Revenue 0 0 0 0
EBITDA (22,944) (18,474) (11,765) (10,530)
Net Income (23,112) (18,772) (11,715) (10,477)
Total Assets 100,153 112,825 17,761 19,073
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cantargia Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cantargia‘s full profile, request access.

Request a free trial

Cantargia Executive Team (7)

Name Title Board Seat Contact Info
Göran Forsberg Ph.D Chief Executive Officer
Bengt Jöndell Chief Financial Officer
Liselotte Larsson Ph.D Chief Operating Officer
Marcus Jaras Ph.D Co-Founder & Scientific Advisor
Ignacio Garcia-Ribas Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Cantargia Board Members (7)

Name Representing Role Since
Thoas Fioretos Ph.D Self Co-Founder, Board Member & Advisor 000 0000
You’re viewing 1 of 7 board members. Get the full list »

Cantargia Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cantargia Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cantargia‘s full profile, request access.

Request a free trial

Cantargia Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 10-Mar-2020 000000000 00000 00 Buildings and Property
To view Cantargia’s complete investments history, request access »